下一代DNA损伤反应抑制剂:利用纳米载体和瘤微环境进行精确的癌症治疗
Abhishikt David Solomon1, Himanshu Kumar Vats2, Shivam Chowdhary3
1Division of Oral and Craniofacial Health Sciences, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Oncology research
|March 9, 2026
概括
下一代DNA损伤反应 (DDR) 抑制剂和纳米药物提供了改进的癌症治疗. 这些方法针对抗药机制和瘤微环境,以获得更有效,更持久的治疗方法.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- DNA损伤反应 (DDR) 对瘤的生存,基因组稳定性和治疗耐药性至关重要.
- 虽然聚 (ADP-ribose) 聚合酶 (PARP) 抑制剂向DDR,但瘤通过适应性修复和微环境因素发展抗性.
研究的目的:
- 审查最近在关键DDR途径和下一代抑制剂方面的进展.
- 分析瘤微环境对DDR依赖性和治疗反应的影响.
- 探索基于纳米载体的新型传递系统,用于增强癌症治疗.
主要方法:
- 综合了DDR通路的最新发现,包括PARP,ATR,ATM,CHK1,WEE1和DNA-PK.
- 分析瘤微环境因素,如缺氧,炎症和免疫细胞.
- 基于纳米载体的传递系统和组合策略的审查.
主要成果:
- 下一代抑制剂显示出增加的选择性和绕过抗性的潜力.
- 瘤微环境组件显著影响DDR依赖性和治疗结果.
- 纳米药物增强药物输送,准耐药,并使组合疗法成为可能.
结论:
- 下一代DDR抑制剂和纳米药物代表了克服癌症治疗耐药性的有希望的战略.
- 在微环境背景的指导下,将DDR抑制剂与免疫疗法和放射疗法结合起来,可以提高治疗疗效.
- 这些进展为更精确,更持久,更个性化的癌症治疗铺平了道路.
相关概念视频
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Site-Targeted Drug Delivery Systems: Polymeric Carriers
71
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
71
Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Modified-Release Drug Delivery Systems: Site-Targeted
60
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
60
Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K


